Samba's 3 Trillion Won Capital Increase... What Shareholders Still Need Explained [Click-e-Stock]

3 Trillion Won Shareholder-Allotted Capital Increase for PolyPeptide Acquisition
Criticism Over "Disappointing Funding Method"
Shin Young Securities: "Need to Demonstrate Investment Plans and Progress"

Samsung Biologics has decided on a rights offering for existing shareholders worth approximately 3 trillion won. The move is aimed at financing the acquisition of Polypeptide Group (PPG), a Swiss peptide contract development and manufacturing organization (CDMO). The main issue is not the capital increase itself, but its sequence. Some are questioning whether the company adequately explained and convinced shareholders regarding its mid- to long-term investment plans before turning to them for funding.

"Rights Offering Was the Last Option"—Changed in a Month

On the 1st, Shin Young Securities maintained its 'buy' rating on Samsung Biologics but expressed disappointment over the company’s choice to rely solely on a shareholder allocation rights offering as its funding method.

Previously, on August 28, Samsung Biologics announced a rights offering plan with a general public offering for forfeited shares. The planned issue involves 2,270,000 common shares at a projected price of KRW 1,322,000 per share. The total amount to be raised is approximately 3 trillion won. Of this, 2.7 trillion won will be used for the PPG acquisition, and around 295 billion won will go toward other facility investments.

The company's explanation is clear. With high interest rates increasing bond issuance costs, fully resorting to borrowing would quickly raise the debt ratio and dependence on borrowed funds. In addition, the company noted that a substantial portion of its investment plans through 2034 are front-loaded, requiring a proactive approach to secure liquidity in advance.

The market, however, remains uneasy. At the time of the PPG acquisition announcement in July, Samsung Biologics stated that it was considering various funding options—including loans, bonds, and a rights offering—but that the rights offering was the lowest priority. Less than a month later, the company decided to proceed with a shareholder allocation rights offering. From an investor perspective, questions such as "Why now?" and "Why a full rights offering?" are inevitable under these circumstances.

The Gap Between Plans and Reality: "Need to Address Investor Concerns"

The company’s ambitious mid- to long-term investment plan worth 15.4 trillion won was also cited as a source of investor anxiety. Samsung Biologics is planning to allocate 2.71 trillion won for the PPG acquisition, 1.9 trillion won for expansion of its 6th plant, 7 trillion won for expanding its third bio campus, 1.76 trillion won for its 7th plant, 690 billion won for a US plant, and 1.34 trillion won for other investments. In terms of scale, this blueprint signals the company’s intention to elevate itself to the next level as a global CDMO player.

However, a blueprint does not automatically inspire confidence. Concerns persist over slowing profitability and marketability of core businesses due to maturation in the antibody CDMO market, as well as potential weakening of order competitiveness stemming from labor union issues. Additionally, the company's competitiveness in next-generation modalities may not yet be sufficiently proven. Research analyst Jeong Yu-kyung at Shin Young Securities pointed out, "The order pipeline for the 5th plant and US plant, the operational rate of the new ADC CDMO, and the groundbreaking timing for the 6th plant have not been fully disclosed, leading to waning market trust in the company's investment plans."

The same applies to the PPG acquisition. While securing a new peptide CDMO modality is meaningful, critics argue that the company’s explanation is lacking when it comes to PPG’s specific technological strengths, competitive order capabilities, synergy with affiliates, and mid- to long-term utilization plans. Analyst Jeong noted, "The company improved profitability by separating its relatively low-margin biosimilar business, but now it's spending 2.7 trillion won to acquire another lower-margin company, PPG," and added, "It’s still unclear how the high purchase price will be justified and how PPG will contribute to Samsung Biologics’ financial position."

Jeong also noted that the rights offering has a clear purpose, and with dilution limited to around 5%, it is unlikely to cause major share price fluctuations. Nonetheless, she expressed concern over possible negative impact on market sentiment. She emphasized, "Whether Samsung C&T and Samsung Electronics—expected to participate with approximately 1.29 trillion won and 940 billion won, respectively—join the rights offering will be a key factor for investor sentiment," and continued, "It is essential for the company to provide thorough explanations and demonstrate progress on its announced plans to confirm long-term corporate value."

This content was produced with the assistance of AI translation services.